Sustained reactivation of mutant p53 drives durable anti-tumor activity across models, including KRAS co-mutant tumors FMC-220 selectively stabilizes p53 Y220C at lower doses, overcoming key ...

Read on to explore recent findings on p53 tumor suppression ... Issue of Cell Death & Differentiation brings together a set of reviews focused on human organoids. Pioneers of the field discuss ...

CAMBRIDGE, MA and ROCKVILLE, MD, USA I April 28, 2025 I Clasp Therapeutics, a biotechnology company bringing unparalleled precision to immuno-oncology with ...